Clinical Trial Update: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of CD73 inhibitor LY3475070 alone or with pembrolizumab in adults with advanced cancer completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• LY3475070 (LY3475070)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Advanced Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-04-05